<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &#x00026; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23837919</article-id><article-id pub-id-type="pmc">3711837</article-id><article-id pub-id-type="publisher-id">1758-5996-5-35</article-id><article-id pub-id-type="doi">10.1186/1758-5996-5-35</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The metabolic cost of lowering blood pressure with hydrochlorothiazide</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Price</surname><given-names>Angela L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>angela.price@utsouthwestern.edu</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>Lingvay</surname><given-names>Ildiko</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ildiko.lingvay@utsouthwestern.edu</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Szczepaniak</surname><given-names>Edward W</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>edward.szczepaniak@cshs.org</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Wiebel</surname><given-names>Jaime</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jwiebel@med.wayne.edu</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Victor</surname><given-names>Ronald G</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ronald.victor@cshs.org</email></contrib><contrib contrib-type="author" corresp="yes" id="A6"><name><surname>Szczepaniak</surname><given-names>Lidia S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>lidia.szczepaniak@cshs.org</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA</aff><aff id="I2"><label>2</label>Cedars -Sinai Medical Center, The Heart Institute, Los Angeles, California, USA</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>9</day><month>7</month><year>2013</year></pub-date><volume>5</volume><fpage>35</fpage><lpage>35</lpage><history><date date-type="received"><day>9</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>5</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Price et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Price et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.dmsjournal.com/content/5/1/35"/><abstract><sec><title>Background</title><p>The landmark Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) placed a new spotlight on thiazide diuretics as the first-line therapy for hypertension. This is concerning as thiazide-diuretics may contribute to comorbidities associated with the current epidemic of obesity. Previous randomized clinical trials have linked thiazide diuretic treatment to insulin resistance, metabolic syndrome, and increased incidence of type 2 diabetes.</p></sec><sec><title>Methods</title><p>This proof of concept, longitudinal, randomized, double&#x02013;blind study evaluated the effects of the angiotensin II receptor blocker Valsartan and the specific thiazide diuretic Hydrochlorothiazide (HCTZ) on hepatic triglyceride level (primary outcome), as well as triglyceride levels within other organs including the heart, skeletal muscle, and pancreas. Additionally, we evaluated whether myocardial function, insulin sensitivity, and insulin secretion were affected by these treatments.</p></sec><sec><title>Results</title><p>Hepatic TG levels increased by 57% post HCTZ treatment: &#x02206;hTG <sub>HCTZ</sub>&#x02009;=&#x02009;4.12% and remained unchanged post Valsartan treatment: &#x02206;hTG <sub>V</sub>&#x02009;=&#x02009;0.06%. The elevation of hepatic TG levels after HCTZ treatment was additionally accompanied by a reduction in insulin sensitivity: &#x02206;SI <sub>HCTZ</sub>&#x02009;=&#x02009;-1.14. Treatment with Valsartan resulted in improved insulin sensitivity: &#x02206;SI <sub>V</sub>&#x02009;=&#x02009;1.24. Treatment-induced changes in hepatic TG levels and insulin sensitivity were statistically significant between groups (p<sub>hTG</sub>&#x02009;=&#x02009;0.0098 and p<sub>SI</sub>&#x02009;=&#x02009;0.0345 respectively). Disposition index, DI, remained unchanged after HCTZ treatment: &#x02206;DI <sub>HCTZ</sub>&#x02009;=&#x02009;-141 but it was increased by a factor of 2 after treatment with Valsartan: &#x02206;DI <sub>V</sub> =1018). However, the change between groups was not statistically significant. Both therapies did not modify abdominal visceral and subcutaneous fat mass as well as myocardial structure and function. Additionally, myocardial, pancreatic, and skeletal muscle triglyceride deposits remained unchanged in both therapeutic arms.</p></sec><sec><title>Conclusions</title><p>Our findings are two-fold and relate to hepatic steatosis and insulin sensitivity. HCTZ treatment worsened hepatic steatosis measured as hepatic triglyceride content and reduced insulin sensitivity. Valsartan treatment did not affect hepatic triglyceride levels and improved insulin sensitivity. The results of this study reinforce the message that in patients at risk for type 2 diabetes it is particularly important to choose an antihypertensive regimen that lowers blood pressure without exacerbating patient&#x02019;s metabolic profile.</p></sec></abstract><kwd-group><kwd>Type 2 diabetes</kwd><kwd>Valsartan</kwd><kwd>Hydrochlorothiazide</kwd><kwd>Proton magnetic resonance spectroscopy</kwd><kwd>Insulin sensitivity</kwd><kwd>Insulin secretion</kwd></kwd-group></article-meta></front><body><sec><title/><p>The incidence of obesity and obesity-related complications such as hypertension and type 2 diabetes are rising steadily despite the increased public and scientific awareness of this multifactorial problem. Although specific efforts to turn the obesity tide concentrate on the development of new treatment strategies, it is important to revisit old therapies and review their side effect profiles as some treatments may silently augment the metabolic syndrome.</p><p>The landmark Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) placed a new spotlight on thiazide diuretics as the first-line therapy for hypertension [<xref ref-type="bibr" rid="B1">1</xref>].This is concerning as thiazide-diuretics may contribute to comorbidities associated with the current epidemic of obesity. Previous randomized clinical trials have linked treatment with thiazide diuretic to insulin resistance, metabolic syndrome, and increased incidence of type 2 diabetes [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>].</p><p>On the contrary, evidence accumulates that therapies which interfere with the adverse metabolic effects of angiotensin II, such as angiotensin II receptor blocking (ARB) or/and angiotensin converting enzyme (ACE I) therapies, cause no metabolic harm as confirmed by the DREAM [<xref ref-type="bibr" rid="B4">4</xref>] and NAVIGATOR [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>] studies. The favorable metabolic action of ARB and ACE-I agents could originate from improvement of insulin sensitivity [<xref ref-type="bibr" rid="B8">8</xref>] or could be facilitated through the recruitment and differentiation of adipocytes [<xref ref-type="bibr" rid="B9">9</xref>]. Both mechanisms could lead to reduction in ectopic deposition of triglyceride in organs such as liver, heart, pancreas and skeletal muscle, a hypothesis that has not yet been tested.</p><p>We present the results of a randomized study comparing the metabolic effects of treatment with hydrochlorothiazide (HCTZ) and Valsartan in individuals at high risk for development of type 2 diabetes. We specifically evaluated the effect of these treatments on intra-hepatic triglyceride content as well as insulin sensitivity, beta-cell function, and ectopic triglyceride deposition in the heart, pancreas, and skeletal muscle.</p></sec><sec sec-type="methods"><title>Methods</title><p>This proof of concept, longitudinal, randomized, double&#x02013;blind study evaluated two antihypertensive treatments in individuals at high risk for diabetes. The study was registered as clinical trial # NCT00745953. The research protocol was approved by Institutional Review Board at UT Southwestern Medical Center. All participants gave informed written consent prior to experiments.</p><p>Our objective was to compare the effects of the angiotensin II receptor blocker Valsartan and the thiazide diuretic Hydrochlorothiazide (HCTZ) on hepatic triglyceride level (primary outcome), as well as triglyceride levels within other organs including the heart, skeletal muscle, and pancreas. Additionally, we evaluated whether myocardial function, insulin sensitivity, and insulin secretion were affected by these treatments.</p><sec><title>Study subjects</title><p>Eighty-two individuals were screened for eligibility to participate in the study. Qualifying individuals were young adults (age range 18&#x02013;55&#x000a0;years)with 3 of the following 5 conditions: fasting glucose&#x02009;&#x0003e;&#x02009;100&#x000a0;mg/dl; waist circumference: men&#x02009;&#x0003e;&#x02009;102&#x000a0;cm, women &#x0003e;88&#x000a0;cm; HDL: men&#x02009;&#x0003c;&#x02009;40&#x000a0;mg/dl, women &#x0003c;50&#x000a0;mg/dl; TG&#x02009;&#x0003e;&#x02009;150&#x000a0;mg/dl; BP&#x02009;&#x0003e;&#x02009;130/85&#x000a0;mm Hg. Individuals with a previous diagnosis of type 2 diabetes, stage 2 hypertension (BP&#x02009;&#x0003e;&#x02009;160/110&#x000a0;mm Hg), or those exposed to thiazolidinediones, statins, diuretics, ARB, ACEI, or any investigational agents within 6&#x000a0;months prior to the study did not qualify. Claustrophobia and presence of metallic implants in the body were magnetic resonance imaging (MRI) exclusion criteria. Additionally, women of child bearing age who were not using reliable contraception or those breast feeding did not qualify.</p><p>Twenty-six individuals who qualified and agreed to participate were randomized in blocks of 4 to either therapy (12 to HCTZ and 14 to Valsartan). Eight individuals (5 in HCTZ and 3 in Valsartan) did not complete the protocol for various personal reasons. Results from 4 individuals who completed therapy (1 in HCTZ and 3 in Valsartan) were excluded from analysis due to either significant lifestyle changes (N&#x02009;=&#x02009;1) that resulted in a large amount of weight loss or because individuals were not available for the end-of-study evaluation (N&#x02009;=&#x02009;3). Fourteen individuals (6 in HCTZ and 8 in Valsartan) completed all study procedures and were considered in final analysis (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Study consort diagram.</p></caption><graphic xlink:href="1758-5996-5-35-1"/></fig></sec><sec><title>Experimental protocol</title><p>Qualified participants were randomized to once-daily 320&#x000a0;mg Valsartan or 25&#x000a0;mg HCTZ therapy for 8&#x000a0;months, with both agents started at half dose and increased to full dose after the first month. Notably, one study subject did not tolerate full dose Valsartan due to relative hypotension and was; therefore, continued on half dose (Valsartan 160&#x000a0;mg) for the entire study duration. All study measurements and procedures were performed at baseline, 1&#x02013;7&#x000a0;days prior to randomization and repeated at the end of the 8-month treatment period.</p></sec><sec><title>Procedures</title><sec><title><italic>Oral glucose tolerance test (OGTT)</italic></title><p>A standard 75&#x000a0;g oral glucose tolerance test was administered only at baseline to evaluate each study subject&#x02019;s glycemic status according to American Diabetes Association criteria [<xref ref-type="bibr" rid="B10">10</xref>], and to screen for the presence of undiagnosed diabetes. The test was performed at 8:30&#x000a0;AM after an overnight fast (10&#x02013;12&#x000a0;hrs) and within 10&#x000a0;days of all other baseline measurements. Blood was sampled at baseline: time &#x02018;0&#x02019; and following the standard glucose drink at 15, 30, 60, 120, and 180&#x000a0;minutes.</p></sec><sec><title><italic>Frequently sampled intravenous glucose tolerance test (FSIVGTT)</italic></title><p>The protocol was initiated at 8:30&#x000a0;AM after an overnight fast (10&#x02013;12&#x000a0;hours). Two intravenous (antecubical vein) polyethylene catheters were inserted, one for infusions of glucose and regular human insulin and another for blood sampling. A bolus of 50% dextrose solution (0.3&#x000a0;g/kg body weight) was injected at time 0 and a bolus of regular human insulin (0.03 U/kg body weight) was injected at 20&#x000a0;min. Blood samples were collected for determination of plasma glucose and insulin levels at: -15, -10, -5, -1, 2, 3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and 180&#x000a0;minutes. Data were analyzed using the Millennium Minimal Model (MINMOD) [<xref ref-type="bibr" rid="B11">11</xref>]. We report the Acute Insulin Response to glucose (AIR<sub>g</sub>) &#x02013; a measure of glucose stimulated insulin secretion, Insulin Sensitivity (SI), and Disposition Index (DI) &#x02013; a measure of insulin secretion adjusted for the prevailing insulin sensitivity which predicts progression to type 2 diabetes [<xref ref-type="bibr" rid="B11">11</xref>].</p></sec><sec><title><italic>Proton magnetic resonance spectroscopy (MRS)</italic></title><p>To study the role of steatosis in the clinical setting, we and others have developed non-invasive, in vivo technique that permits the precise and reproducible quantification of intracellular triglyceride in various human organs, including skeletal muscle [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B15">15</xref>], liver [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>], myocardium [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B21">21</xref>], and pancreas [<xref ref-type="bibr" rid="B22">22</xref>]. This method offers a technological advantage as it distinguishes the large compartments of triglyceride in adipose tissue cells from the triglyceride droplets that are stored within the cytosol of parenchymal cells. This method is now widely accepted and has become extremely useful in obesity and diabetes clinical studies as these evaluations are fast, safe, and reliable. In this study, we evaluated hepatic, pancreatic, myocardial and skeletal muscle TG content using a1.5 Tesla Gyroscan Achieva whole body clinical system (Philips Medical Systems, Cleveland, USA) equipped with software for localized spectroscopy as described before [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>].In short, high-resolution morphological images were collected to serve as a &#x0201c;roadmap&#x0201d; for selection of a testing volume of 27&#x000a0;cc within the upper right hepatic lobe, 2&#x000a0;cc within pancreatic tail, 6&#x000a0;cc in myocardial septum, and 1&#x000a0;cc within the skeletal muscle.All spectra were collected using PRESS sequence (Point RESolved Spectroscopy) for spatial localization and the signal acquisition with the following data acquisition pmeters: T<sub>e</sub>&#x02009;=&#x02009;27&#x000a0;ms, T<sub>r</sub>&#x02009;=&#x02009;3&#x000a0;s. All data were collected without water suppression. Sixteen acquisitions were averaged for liver, pancreas, and skeletal muscle, and 32 for heart. Areas of resonances from protons in water molecules and in methylenes of fatty acid chains were evaluated with line-fit procedure using a commercial software (NUTS-ACORNNMR, Freemont, CA) [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B17">17</xref>].</p></sec></sec><sec><title>Cardiac imaging</title><p>Dynamic cine images were used to quantify left ventricular (LV) volume [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Image analysis was performed by an observer blinded to the subject&#x02019;s clinical history and treatment, using a commercially available workstation (MASS, Philips Medical Systems). Endocardial and epicardial LV borders were traced manually at end diastole and end systole from short-axis slices, and the papillary muscles were excluded from the LV cavity volume. LV mass was computed as the product of end-diastolic LV volume and myocardial density (1.05&#x000a0;g/mL). The fraction of blood pumped out of the left ventricle with each heart beat, the ejection fraction (EF), was calculated as the difference between left ventricular end diastolic volume and left ventricular end systolic volume divided by left ventricular end diastolic volume. EF was used as an index of global LV function.</p></sec><sec><title>Abdominal MRI</title><p>The amount of subcutaneous and visceral abdominal fat was determined from a single abdominal axial image at the level between vertebral bodies L2 and L3 [<xref ref-type="bibr" rid="B23">23</xref>]. The image analysis was performed by a single observer who was blinded to the volunteer&#x02019;s treatment, using commercially available software (MASS, Philips Medical Systems) that maps the subcutaneous and intra-abdominal adipose tissue compartments.</p></sec><sec><title>Laboratory measurements</title><p>All blood was processed immediately and was analyzed within 7&#x000a0;days. Lipid profile, liver function tests, glucose, and insulin were analyzed in a commercial laboratory, Quest Diagnostics, Irving, TX. HbA1c was analyzed by HPLC at UT Southwestern Medical Center.</p></sec><sec><title>Clinical measurements</title><p>Blood pressure was measured with a Space Labs continuous home monitor for at least a 24&#x000a0;hr period. The average of all results obtained during this monitoring period is reported. Waist circumference was measured at the level of the umbilicus in neutral respiratory position, using the same standard tape for all measurements during the entire study. Hip circumference was measured at the widest part of the hips.</p></sec><sec><title>Statistics</title><p>Responses to therapies, measured as a difference between baseline and end of the study, were compared between the groups. The tests for normality (Shapiro-Wilk, chi-square and Kolmogorov-Smirnov) showed that the hepatic triglyceride content (hTG) response to HCTZ and disposition index - DI response to Valsartan were not normally distributed with 95% of confidence based on the results of at least one of the listed tests. All other responses, including SI response to both treatments were normally distributed with 95% confidence. Therefore we used two sample t-test for comparison of the central tendency for SI between the two groups. The F-test was used to compare the variability of the responses between the two groups. We used non-pmetric Wilcoxon-Mann&#x02013;Whitney test to compare hTG and DI responses. Data were analyzed with Statgraphics Centurion XVI software. Statistical significance was set at p&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The characteristics of study participants and the main study results are listed in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref> and Table&#x000a0;<xref ref-type="table" rid="T2">2</xref> respectively. Demographic, clinical, and biochemical characteristics of both groups were similar at baseline and did not change following either treatment. However, hepatic TG levels, a measure of hepatic steatosis, increased by 57% after HCTZ (baseline average hTG&#x02009;=&#x02009;7.18% +/- 3.30%, hTG range 0.59% - 21.97%; post HCTZ average hTG&#x02009;=&#x02009;11.30% +/- 4.56%, hTG range 3.13% - 32.37%; and &#x00394;hTG <sub>HCTZ</sub>&#x02009;=&#x02009;4.12%). Hepatic TG levels were unchanged after Valsartan therapy (baseline average hTG&#x02009;=&#x02009;8.21% +/- 3.90%, hTG range 1.62% - 34.92%; post Valsartan average hTG&#x02009;=&#x02009;8.27% +/- 3.38%, hTG range 2.83% - 31.49%, and &#x00394;hTG <sub>V</sub>&#x02009;=&#x02009;0.06%). The increased inhepatic TG levels in the HCTZ group were accompanied by a reduction in insulin sensitivity (baseline average SI&#x02009;=&#x02009;3.71 +/- 0.98, SI range 1.17 - 7.78; post HCTZ average SI&#x02009;=&#x02009;2.57 +/- 0.20, SI range 1.66-3.04; and &#x00394;SI <sub>HCTZ</sub>&#x02009;=&#x02009;-1.14). Treatment with Valsartan resulted in improved insulin sensitivity (baseline average SI&#x02009;=&#x02009;2.27 +/- 0.68, SI range 0.46- 6.67; post Valsartan average SI 3.51 +/- 0.80, SI range 1.28-7.42; and &#x00394;SI <sub>V</sub>&#x02009;=&#x02009;1.24). Treatment-induced changes in hepatic TG levels and insulin sensitivity were statistically significant between groups (p<sub>hTG</sub>&#x02009;=&#x02009;0.0098and p<sub>SI</sub>&#x02009;=&#x02009;0.0345 respectively). The individual results as well as the changes in hTG and SI are shown in Figures&#x000a0;<xref ref-type="fig" rid="F2">2</xref> and <xref ref-type="fig" rid="F3">3</xref>.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Impact of hydrochlorothiazide (HCTZ) and Valsartan treatments on hepatic triglyceride levels (hTG) and insulin sensitivity (SI).</bold> Results of hTG and SI are color coded relative to patient. Black points represent the averages.</p></caption><graphic xlink:href="1758-5996-5-35-2"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>(a) </bold><bold>Changes in hepatic triglyceride content (hTG) after treatment with Valsartan and HCTZ ( p&#x02009;=&#x02009;0.0098). </bold><bold>(b)</bold> Changes in insulin sensitivity (SI) after treatment with HCTZ and Valsartan (p&#x02009;=&#x02009;-0.0345).</p></caption><graphic xlink:href="1758-5996-5-35-3"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of study participants (mean &#x000b1; standard error)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="2" align="center" valign="bottom"><bold>HCTZ</bold><hr/></th><th colspan="2" align="center" valign="bottom"><bold>Valsartan</bold><hr/></th></tr><tr><th align="left"><bold>Variable</bold></th><th align="center"><bold>Baseline</bold></th><th align="center"><bold>End</bold></th><th align="center"><bold>Baseline</bold></th><th align="center"><bold>End</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>N</bold><hr/></td><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">9<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Male</bold>, %<hr/></td><td align="center" valign="bottom"><bold>71</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom"><bold>22</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age</bold>, years<hr/></td><td align="center" valign="bottom"><bold>35</bold> &#x000b1; 11<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom"><bold>37</bold> &#x000b1; 5<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Hip</bold> circumference, cm<hr/></td><td align="center" valign="bottom"><bold>110</bold> &#x000b1; 6<hr/></td><td align="center" valign="bottom"><bold>115</bold> &#x000b1; 9<hr/></td><td align="center" valign="bottom"><bold>116</bold> &#x000b1; 10<hr/></td><td align="center" valign="bottom"><bold>116</bold> &#x000b1; 10<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Waist</bold> circumference, cm<hr/></td><td align="center" valign="bottom"><bold>101</bold> &#x000b1; 12<hr/></td><td align="center" valign="bottom"><bold>104</bold> &#x000b1; 16<hr/></td><td align="center" valign="bottom"><bold>107</bold> &#x000b1; 9<hr/></td><td align="center" valign="bottom"><bold>107</bold> &#x000b1; 11<hr/></td></tr><tr><td align="left" valign="bottom"><bold>BMI</bold>, kg/m<sup>2</sup><hr/></td><td align="center" valign="bottom"><bold>30.7</bold> &#x000b1; 2.4<hr/></td><td align="center" valign="bottom"><bold>31.6</bold> &#x000b1; 2.7<hr/></td><td align="center" valign="bottom"><bold>34.7</bold> &#x000b1; 3.4<hr/></td><td align="center" valign="bottom"><bold>34.9</bold> &#x000b1; 3.9<hr/></td></tr><tr><td align="left" valign="bottom"><bold>SBP</bold>, mmHg<hr/></td><td align="center" valign="bottom"><bold>120</bold> &#x000b1; 11<hr/></td><td align="center" valign="bottom">119 &#x000b1; 9<hr/></td><td align="center" valign="bottom"><bold>114</bold> &#x000b1; 8<hr/></td><td align="center" valign="bottom"><bold>108</bold> &#x000b1; 9<hr/></td></tr><tr><td align="left" valign="bottom"><bold>DBP</bold>, mmHg<hr/></td><td align="center" valign="bottom"><bold>72</bold> &#x000b1; 8<hr/></td><td align="center" valign="bottom">71 &#x000b1; 5<hr/></td><td align="center" valign="bottom"><bold>71</bold> &#x000b1; 7<hr/></td><td align="center" valign="bottom"><bold>67</bold> &#x000b1; 5<hr/></td></tr><tr><td align="left" valign="bottom"><bold>HR</bold>, beat/min<hr/></td><td align="center" valign="bottom"><bold>74</bold> &#x000b1; 9<hr/></td><td align="center" valign="bottom"><bold>77</bold> &#x000b1; 8<hr/></td><td align="center" valign="bottom"><bold>80</bold> &#x000b1; 7<hr/></td><td align="center" valign="bottom"><bold>81</bold> &#x000b1; 7<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Glucose</bold>, mg/dL<hr/></td><td align="center" valign="bottom"><bold>95</bold> &#x000b1; 11<hr/></td><td align="center" valign="bottom"><bold>98</bold> &#x000b1; 11<hr/></td><td align="center" valign="bottom"><bold>100</bold> &#x000b1; 10<hr/></td><td align="center" valign="bottom"><bold>94</bold> &#x000b1; 11<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Insulin</bold>, /mL<hr/></td><td align="center" valign="bottom"><bold>7</bold> &#x000b1; 6<hr/></td><td align="center" valign="bottom"><bold>8</bold> &#x000b1; 4<hr/></td><td align="center" valign="bottom"><bold>7</bold> &#x000b1; 5<hr/></td><td align="center" valign="bottom"><bold>9</bold> &#x000b1; 7<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Cholesterol</bold>, mg/dL<hr/></td><td align="center" valign="bottom"><bold>209</bold> &#x000b1; 17<hr/></td><td align="center" valign="bottom"><bold>217</bold> &#x000b1; 34<hr/></td><td align="center" valign="bottom"><bold>194</bold> &#x000b1; 40<hr/></td><td align="center" valign="bottom"><bold>192</bold> &#x000b1; 30<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Triglycerides</bold>, mg/dL<hr/></td><td align="center" valign="bottom"><bold>182</bold> &#x000b1; 118<hr/></td><td align="center" valign="bottom"><bold>186</bold> &#x000b1; 52<hr/></td><td align="center" valign="bottom"><bold>153</bold> &#x000b1; 106<hr/></td><td align="center" valign="bottom"><bold>151</bold> &#x000b1; 83<hr/></td></tr><tr><td align="left" valign="bottom"><bold>HDL</bold>, mg/dL<hr/></td><td align="center" valign="bottom"><bold>40</bold> &#x000b1; 8<hr/></td><td align="center" valign="bottom"><bold>41</bold> &#x000b1; 6<hr/></td><td align="center" valign="bottom"><bold>47</bold> &#x000b1; 14<hr/></td><td align="center" valign="bottom"><bold>49</bold> &#x000b1; 20<hr/></td></tr><tr><td align="left" valign="bottom"><bold>LDL</bold>, mg/dL<hr/></td><td align="center" valign="bottom"><bold>142</bold> &#x000b1; 17<hr/></td><td align="center" valign="bottom"><bold>139</bold> &#x000b1; 32<hr/></td><td align="center" valign="bottom"><bold>119</bold> &#x000b1; 31<hr/></td><td align="center" valign="bottom"><bold>113</bold> &#x000b1; 27<hr/></td></tr><tr><td align="left" valign="bottom"><bold>HbA1c</bold>, %<hr/></td><td align="center" valign="bottom"><bold>5.4</bold> &#x000b1; 0.1<hr/></td><td align="center" valign="bottom"><bold>55</bold> &#x000b1; 0.3<hr/></td><td align="center" valign="bottom"><bold>5.4</bold> &#x000b1; 0.5<hr/></td><td align="center" valign="bottom"><bold>55</bold> &#x000b1; 0.3<hr/></td></tr><tr><td align="left" valign="bottom"><bold>ALT</bold>, u/L<hr/></td><td align="center" valign="bottom"><bold>31</bold> &#x000b1; 8<hr/></td><td align="center" valign="bottom"><bold>31</bold> &#x000b1; 12<hr/></td><td align="center" valign="bottom"><bold>27</bold> &#x000b1; 25<hr/></td><td align="center" valign="bottom"><bold>22</bold> &#x000b1; 15<hr/></td></tr><tr><td align="left"><bold>AST</bold>, u/L</td><td align="center"><bold>29</bold> &#x000b1; 8</td><td align="center"><bold>26</bold> &#x000b1; 6</td><td align="center"><bold>21</bold> &#x000b1; 11</td><td align="center"><bold>19</bold> &#x000b1; 6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p><bold>Hepatic triglyceride content (hTG), insulin secretion (SI) glucose stimulated insulin response (AIR</bold><sub><bold>g</bold></sub><bold>) and disposition index (DI) following the eight months treatment with either hydrochlorothiazide (HCTZ) or Valsartan (mean &#x000b1; standard error)</bold></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="2" align="center" valign="bottom"><bold>HCTZ</bold><hr/></th><th colspan="2" align="center" valign="bottom"><bold>Valsartan</bold><hr/></th></tr><tr><th align="left"><bold>Variable</bold></th><th align="center"><bold>Baseline</bold></th><th align="center"><bold>End</bold></th><th align="center"><bold>Baseline</bold></th><th align="center"><bold>End</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>hTG,</bold> f/w, %<hr/></td><td align="center" valign="bottom"><bold>7.18</bold> &#x000b1; 3.30<hr/></td><td align="center" valign="bottom"><bold>11.53</bold> &#x000b1; 4.56<hr/></td><td align="center" valign="bottom"><bold>8.29</bold> &#x000b1; 3.90<hr/></td><td align="center" valign="bottom"><bold>8.27</bold> &#x000b1; 3.38<hr/></td></tr><tr><td align="left" valign="bottom"><bold>SI,</bold> (x10<sup>-5</sup>/min pmol/l)<hr/></td><td align="center" valign="bottom"><bold>3.72</bold> &#x000b1; 0.98<hr/></td><td align="center" valign="bottom"><bold>2.57</bold> &#x000b1; 0.02<hr/></td><td align="center" valign="bottom"><bold>2.27</bold> &#x000b1; 0.68<hr/></td><td align="center" valign="bottom"><bold>3.51</bold> &#x000b1; 0.8<hr/></td></tr><tr><td align="left" valign="bottom"><bold>AIR</bold><sub><bold>g</bold></sub><bold>,</bold> pmol/l<hr/></td><td align="center" valign="bottom"><bold>445</bold> &#x000b1; 291<hr/></td><td align="center" valign="bottom"><bold>466</bold> &#x000b1; 263<hr/></td><td align="center" valign="bottom"><bold>701</bold> &#x000b1; 608<hr/></td><td align="center" valign="bottom"><bold>708</bold> &#x000b1; 405<hr/></td></tr><tr><td align="left"><bold>DI,</bold> (x10<sup>-5</sup>/min)</td><td align="center"><bold>1332</bold> &#x000b1; 399</td><td align="center"><bold>1191</bold> &#x000b1; 312</td><td align="center"><bold>1016</bold> &#x000b1; 157</td><td align="center"><bold>2034</bold> &#x000b1; 566</td></tr></tbody></table><table-wrap-foot><p>Of note: <italic>DI</italic>, SI*AIRg and describes the progression to type 2 diabetes when lowered or improvement of metabolic status when raised [<xref ref-type="bibr" rid="B11">11</xref>].</p></table-wrap-foot></table-wrap><p>DI remained unchanged after HCTZ treatment (baseline average DI&#x02009;=&#x02009;1332 +/- 399, DI range 471&#x02013;3255; post HCTZ average DI&#x02009;=&#x02009;1191 +/- 312, DI range 372&#x02013;2339; and &#x00394;DI <sub>HCTZ</sub>&#x02009;=&#x02009;-141) but DI increased by a factor of 2 after treatment with Valsartan (baseline average DI&#x02009;=&#x02009;1016 +/- 157, DI range 473&#x02013;1819; post Valsartan average DI 2034 +/- 556, DI range 737 &#x02013; 5739; and &#x00394;DI <sub>V</sub> =1018) &#x02013; primarily due to improvement in SI. However, there change between treatment groups was not significant. Abdominal (visceral) and subcutaneous fat mass as well as myocardial structure and function remained unchanged in both therapeutic arms. Additionally, we did not detect significant changes in myocardial, pancreatic, and skeletal muscle triglyceride deposits with these interventions.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>We have demonstrated a differential metabolic effect of two frequently prescribed antihypertensive agents in individuals at risk for type 2 diabetes. The findings of our study relate to hepatic steatosis and insulin sensitivity. HCTZ treatment worsened hepatic steatosis measured as hepatic TG content and reduced insulin sensitivity. Valsartan treatment did not affect hepatic TG levels and improved insulin sensitivity. The results of this study reinforce the message that in patients at risk for type 2 diabetes it is particularly important to choose an antihypertensive regimen that lowers blood pressure without exacerbating patient&#x02019;s metabolic profile.</p><p>Our results pllel the earlier reported findings from the MEDICA study [<xref ref-type="bibr" rid="B24">24</xref>]. MEDICA investigators reported similar worsening in hepatic triglyceride content and insulin sensitivity following 3&#x000a0;months of treatment with 50&#x000a0;mg of HCTZ and observed no change of hepatic triglyceride levels following treatment with another ARB class medication Candesartan. In light of such tight agreement of two independent studies, therapy with HCTZ - widely accepted as first-line agent for treating hypertension - should be re-evaluated. HCTZ offer affordable and efficient blood pressure lowering but come with the added cost of worsening metabolic profiles for diabetes. This can occur even at doses of 25&#x000a0;mg and is sustained over a longer treatment period (8&#x000a0;months). By the same means, the ARB agents improve insulin sensitivity and did not cause fatty liver.</p><p>Primum non nocere - our treatment choices should not only improve the primary condition for which they are prescribed, but we must ensure that our patients suffer no harm. The ultimate goal of any antihypertensive therapy is to prevent cardiovascular events. The use of an antihypertensive agent that worsens hepatic steatosis and insulin resistance, both of which promote cardiovascular disease, negates the ultimate cardiovascular-preventive goal of the treatment. Hypertension clusters with metabolic syndrome, diabetes, and hepatic steatosis, and requires life-long pharmacologic treatment. When all aspects are balanced i.e. the blood pressure lowering effect and the worsening metabolic profile the use of HCTZ as a first line therapeutic choice should be questioned.</p><p>The underlying mechanism of the deleterious metabolic action of HCTZ is still debated although our results implicate concomitant worsening of fatty liver and decreased insulin sensitivity. Chronic exposure to angiotensin II may render fat cells less efficient in their capacity to adequately store excess triglyceride, resulting in tissue overflow with ectopic triglyceride and ultimately hepatic steatosis. Interestingly, blocking the renin-angiotensin system by Valsartan did not result in fatty liver. The favorable metabolic action of Valsartan is probably complex and could originate from improvement of insulin sensitivity [<xref ref-type="bibr" rid="B8">8</xref>] or it could be facilitated through the recruitment and differentiation of adipocytes [<xref ref-type="bibr" rid="B25">25</xref>]. In light of the above-mentioned observations it seems natural to hypothesize that pairing ARB with HCTZ could block angiotensin II and mitigate the adverse metabolic effects induced by HCTZ. Regrettably, an attempt to block these unfavorable metabolic effects of HCTZ by combining it with losartan was not successful [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>We acknowledge that this study is small and these results should be replicated, yet the effect size was considerable and very compble to that found in a similar independently conducted study [<xref ref-type="bibr" rid="B24">24</xref>]. We also note that small sample size did not allow us to further explore the mechanisms that contribute to our observations.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>We have documented that HCTZ therapy leads to the development of hepatic steatosis and compromised insulin sensitivity in subjects at high risk for type 2 diabetes. Conversely, treatment with Valsartan did not cause ectopic fat redistribution, and in fact, leads to improved insulin sensitivity. Further studies are needed to determine the exact mechanism by which HCTZ exerts its deleterious effects and whether these changes in metabolic pmeters will translate into an increase in major long-term adverse cardiovascular events. While the clinical relevance of thiazide-induced metabolic derangements remains uncertain at this time, hypertensive individuals at risk for diabetes and those with known hepatic steatosis should opt for antihypertensive agents that are metabolically benign &#x02013; i.e. ARB or ACE inhibitors &#x02013; until this issue is clarified.</p></sec><sec><title>Competing interests</title><p>This study was funded as the investigator initiated research award to LSS and RGB by Novartis.</p></sec><sec><title>Authors&#x02019; contributions</title><p>ALP and IL designed and carried OGTT and FSIVGTT experiments. Participated in results interpretation and writing the manuscript. EWS processed MR imaging and spectroscopy data, participated in data interpretation, and assisted with statistical analysis.JW assisted in GCRC experiments, created and maintained data base for the study, processed FSIVGTT data using MinMode software, contributed to discussion on results interpretation.RGV participated in study design and results interpretation.LSS designed the study, overlooked all study procedures, executed MR Spectroscopy and wrote the paper. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Funding sources</title><p>This study was supported in part by Novartis Investigator Initiated Award, NIH UL1RR024982, NIH K23 RR024470, R01 NIDDK081524.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Barzilay</surname><given-names>JI</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Cutler</surname><given-names>JA</given-names></name><name><surname>Pressel</surname><given-names>SL</given-names></name><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>Basile</surname><given-names>J</given-names></name><name><surname>Margolis</surname><given-names>KL</given-names></name><name><surname>Ong</surname><given-names>ST</given-names></name><name><surname>Sadler</surname><given-names>LS</given-names></name><name><surname>Summerson</surname><given-names>J</given-names></name><article-title>Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</article-title><source>Arch Intern Med</source><year>2006</year><volume>166</volume><fpage>2191</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1001/archinte.166.20.2191</pub-id><pub-id pub-id-type="pmid">17101936</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Stump</surname><given-names>CS</given-names></name><name><surname>Hamilton</surname><given-names>MT</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name><article-title>Effect of antihypertensive agents on the development of type 2 diabetes mellitus</article-title><source>Mayo Clin Proc</source><year>2006</year><volume>81</volume><fpage>796</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.4065/81.6.796</pub-id><pub-id pub-id-type="pmid">16770980</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Elliott</surname><given-names>WJ</given-names></name><name><surname>Meyer</surname><given-names>PM</given-names></name><article-title>Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis</article-title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60108-1</pub-id><pub-id pub-id-type="pmid">17240286</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><name><surname>Pogue</surname><given-names>J</given-names></name><name><surname>Sheridan</surname><given-names>P</given-names></name><name><surname>Dinccag</surname><given-names>N</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Hoogwerf</surname><given-names>B</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name><article-title>Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1096</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">16997664</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Basile</surname><given-names>JN</given-names></name><article-title>Antihypertensive therapy, new-onset diabetes, and cardiovascular disease</article-title><source>Int J Clin Pract</source><year>2009</year><volume>63</volume><fpage>656</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2009.02009.x</pub-id><pub-id pub-id-type="pmid">19220522</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Boolell</surname><given-names>M</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>McMurray</surname><given-names>J</given-names></name><name><surname>Duggal</surname><given-names>A</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name><article-title>Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial</article-title><source>Am Heart J</source><year>2008</year><volume>156</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2008.05.017</pub-id><pub-id pub-id-type="pmid">18946890</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Karnes</surname><given-names>JH</given-names></name><name><surname>Cooper-DeHoff</surname><given-names>RM</given-names></name><article-title>Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects</article-title><source>Expert Rev Cardiovasc Ther</source><year>2009</year><volume>7</volume><fpage>689</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1586/erc.09.31</pub-id><pub-id pub-id-type="pmid">19505284</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Kurtz</surname><given-names>TW</given-names></name><name><surname>Pravenec</surname><given-names>M</given-names></name><article-title>Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system</article-title><source>J Hypertens</source><year>2004</year><volume>22</volume><fpage>2253</fpage><lpage>2261</lpage><pub-id pub-id-type="doi">10.1097/00004872-200412000-00003</pub-id><pub-id pub-id-type="pmid">15614015</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Sharma</surname><given-names>AM</given-names></name><name><surname>Janke</surname><given-names>J</given-names></name><name><surname>Gorzelniak</surname><given-names>K</given-names></name><name><surname>Engeli</surname><given-names>S</given-names></name><name><surname>Luft</surname><given-names>FC</given-names></name><article-title>Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells</article-title><source>Hypertension</source><year>2002</year><volume>40</volume><fpage>609</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000036448.44066.53</pub-id><pub-id pub-id-type="pmid">12411451</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Davidson</surname><given-names>MB</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><name><surname>Henry</surname><given-names>RR</given-names></name><name><surname>Pratley</surname><given-names>R</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name><article-title>Impaired fasting glucose and impaired glucose tolerance: implications for care</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>753</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.2337/dc07-9920</pub-id><pub-id pub-id-type="pmid">17327355</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Bergman</surname><given-names>RN</given-names></name><article-title>Lilly Lecture 1989. Toward Physiological Understanding of Glucose Tolerance. Minimal-Model Approach</article-title><source>Diabetes</source><year>1989</year><volume>38</volume><fpage>1512</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.2337/diabetes.38.12.1512</pub-id><pub-id pub-id-type="pmid">2684710</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Boesch</surname><given-names>C</given-names></name><name><surname>Slotboom</surname><given-names>J</given-names></name><name><surname>Hoppeler</surname><given-names>H</given-names></name><name><surname>Kreis</surname><given-names>R</given-names></name><article-title>In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy</article-title><source>Magn Reson Med</source><year>1997</year><volume>37</volume><fpage>484</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1002/mrm.1910370403</pub-id><pub-id pub-id-type="pmid">9094069</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Schick</surname><given-names>F</given-names></name><name><surname>Eismann</surname><given-names>B</given-names></name><name><surname>Jung</surname><given-names>WI</given-names></name><name><surname>Bongers</surname><given-names>H</given-names></name><name><surname>Bunse</surname><given-names>M</given-names></name><name><surname>Lutz</surname><given-names>O</given-names></name><article-title>Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue</article-title><source>Magn Reson Med</source><year>1993</year><volume>29</volume><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1002/mrm.1910290203</pub-id><pub-id pub-id-type="pmid">8429779</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><name><surname>Babcock</surname><given-names>EE</given-names></name><name><surname>Schick</surname><given-names>F</given-names></name><name><surname>Dobbins</surname><given-names>RL</given-names></name><name><surname>Garg</surname><given-names>A</given-names></name><name><surname>Burns</surname><given-names>DK</given-names></name><name><surname>McGarry</surname><given-names>JD</given-names></name><name><surname>Stein</surname><given-names>DT</given-names></name><article-title>Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo</article-title><source>Am J Physiol</source><year>1999</year><volume>276</volume><fpage>E977</fpage><lpage>E989</lpage><pub-id pub-id-type="pmid">10329993</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><name><surname>Dobbins</surname><given-names>RL</given-names></name><name><surname>Stein</surname><given-names>DT</given-names></name><name><surname>McGarry</surname><given-names>JD</given-names></name><article-title>Bulk magnetic susceptibility effects on the assessment of intra- and extramyocellular lipids in vivo</article-title><source>Magn Reson Med</source><year>2002</year><volume>47</volume><fpage>607</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1002/mrm.10086</pub-id><pub-id pub-id-type="pmid">11870849</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><name><surname>Dobbins</surname><given-names>RL</given-names></name><name><surname>Metzger</surname><given-names>GJ</given-names></name><name><surname>Sartoni-D&#x02019;Ambrosia</surname><given-names>G</given-names></name><name><surname>Arbique</surname><given-names>D</given-names></name><name><surname>Vongpatanasin</surname><given-names>W</given-names></name><name><surname>Unger</surname><given-names>R</given-names></name><name><surname>Victor</surname><given-names>RG</given-names></name><article-title>Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging</article-title><source>Magn Reson Med</source><year>2003</year><volume>49</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/mrm.10372</pub-id><pub-id pub-id-type="pmid">12594743</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><name><surname>Nurenberg</surname><given-names>P</given-names></name><name><surname>Leonard</surname><given-names>D</given-names></name><name><surname>Browning</surname><given-names>JD</given-names></name><name><surname>Reingold</surname><given-names>JS</given-names></name><name><surname>Grundy</surname><given-names>S</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name><name><surname>Dobbins</surname><given-names>RL</given-names></name><article-title>Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population</article-title><source>Am J Physiol Endocrinol Metab</source><year>2005</year><volume>288</volume><fpage>E462</fpage><lpage>E468</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00064.2004</pub-id><pub-id pub-id-type="pmid">15339742</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>McGavock</surname><given-names>JM</given-names></name><name><surname>Victor</surname><given-names>RG</given-names></name><name><surname>Unger</surname><given-names>RH</given-names></name><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><article-title>Adiposity of the heart, revisited</article-title><source>Ann Intern Med</source><year>2006</year><volume>144</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-144-7-200604040-00011</pub-id><pub-id pub-id-type="pmid">16585666</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>McGavock</surname><given-names>JM</given-names></name><name><surname>Lingvay</surname><given-names>I</given-names></name><name><surname>Zib</surname><given-names>I</given-names></name><name><surname>Tillery</surname><given-names>T</given-names></name><name><surname>Salas</surname><given-names>N</given-names></name><name><surname>Unger</surname><given-names>R</given-names></name><name><surname>Levine</surname><given-names>BD</given-names></name><name><surname>Raskin</surname><given-names>P</given-names></name><name><surname>Victor</surname><given-names>RG</given-names></name><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><article-title>Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>1170</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.645614</pub-id><pub-id pub-id-type="pmid">17698735</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Reingold</surname><given-names>JS</given-names></name><name><surname>McGavock</surname><given-names>JM</given-names></name><name><surname>Kaka</surname><given-names>S</given-names></name><name><surname>Tillery</surname><given-names>T</given-names></name><name><surname>Victor</surname><given-names>RG</given-names></name><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><article-title>Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method</article-title><source>Am J Physiol Endocrinol Metab</source><year>2005</year><volume>289</volume><fpage>E935</fpage><lpage>E939</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00095.2005</pub-id><pub-id pub-id-type="pmid">15972271</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Lingvay</surname><given-names>I</given-names></name><name><surname>Raskin</surname><given-names>P</given-names></name><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><article-title>The fatty hearts of patients with diabetes</article-title><source>Nat Rev Cardiol</source><year>2009</year><volume>6</volume><fpage>268</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2009.30</pub-id><pub-id pub-id-type="pmid">19352328</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Lingvay</surname><given-names>I</given-names></name><name><surname>Esser</surname><given-names>V</given-names></name><name><surname>Legendre</surname><given-names>JL</given-names></name><name><surname>Price</surname><given-names>AL</given-names></name><name><surname>Wertz</surname><given-names>KM</given-names></name><name><surname>Adams-Huet</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Unger</surname><given-names>RH</given-names></name><name><surname>Szczepaniak</surname><given-names>LS</given-names></name><article-title>Noninvasive quantification of pancreatic fat in humans</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><fpage>4070</fpage><lpage>4076</lpage><pub-id pub-id-type="doi">10.1210/jc.2009-0584</pub-id><pub-id pub-id-type="pmid">19773401</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Abate</surname><given-names>N</given-names></name><name><surname>Garg</surname><given-names>A</given-names></name><name><surname>Peshock</surname><given-names>RM</given-names></name><name><surname>Stray-Gundersen</surname><given-names>J</given-names></name><name><surname>Grundy</surname><given-names>SM</given-names></name><article-title>Relationships of generalized and regional adiposity to insulin sensitivity in men</article-title><source>J Clin Invest</source><year>1995</year><volume>96</volume><fpage>88</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1172/JCI118083</pub-id><pub-id pub-id-type="pmid">7615840</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Eriksson</surname><given-names>JW</given-names></name><name><surname>Jansson</surname><given-names>PA</given-names></name><name><surname>Carlberg</surname><given-names>B</given-names></name><name><surname>Hagg</surname><given-names>A</given-names></name><name><surname>Kurland</surname><given-names>L</given-names></name><name><surname>Svensson</surname><given-names>MK</given-names></name><name><surname>Ahlstrom</surname><given-names>H</given-names></name><name><surname>Strom</surname><given-names>C</given-names></name><name><surname>Lonn</surname><given-names>L</given-names></name><name><surname>Ojbrandt</surname><given-names>K</given-names></name><name><surname>Johansson</surname><given-names>L</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name><article-title>Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study</article-title><source>Hypertension</source><year>2008</year><volume>52</volume><fpage>1030</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.108.119404</pub-id><pub-id pub-id-type="pmid">18981327</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="other"><name><surname>Sharma</surname><given-names>AM</given-names></name><article-title>Does it matter how blood pressure is lowered in patients with metabolic risk factors?</article-title><source>J Am Soc Hypertens</source><year>2008</year><issue>4</issue><fpage>S23</fpage><lpage>S29</lpage><pub-id pub-id-type="pmid">20409934</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Bakris</surname><given-names>G</given-names></name><name><surname>Molitch</surname><given-names>M</given-names></name><name><surname>Hewkin</surname><given-names>A</given-names></name><name><surname>Kipnes</surname><given-names>M</given-names></name><name><surname>Sarafidis</surname><given-names>P</given-names></name><name><surname>Fakouhi</surname><given-names>K</given-names></name><name><surname>Bacher</surname><given-names>P</given-names></name><name><surname>Sowers</surname><given-names>J</given-names></name><article-title>Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome</article-title><source>Diab Care</source><year>2006</year><volume>29</volume><fpage>2592</fpage><lpage>2597</lpage><pub-id pub-id-type="doi">10.2337/dc06-1373</pub-id></mixed-citation></ref></ref-list></back></article>